
Sign up to save your podcasts
Or


Kelly Dooley (Johns Hopkins University, USA) and Gavin Churchyard (Aurum Institute, South Africa) discuss their trial on tuberculosis prevention in people with HIV taking dolutegravir-based antiretroviral therapy with Deputy Editor Philippa Harris.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
22 ratings
Kelly Dooley (Johns Hopkins University, USA) and Gavin Churchyard (Aurum Institute, South Africa) discuss their trial on tuberculosis prevention in people with HIV taking dolutegravir-based antiretroviral therapy with Deputy Editor Philippa Harris.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

322 Listeners

1,154 Listeners

22 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

6 Listeners

0 Listeners

0 Listeners